Stem cell transplantation for neurometabolic and neurodegenerative diseases

Neuropharmacology

Volumn 58, Issue 6, 2010, Pages 845-854

  Shihabuddin, Lamya S ^a   Aubert, Isabelle ^b,c  

^a GENZYME CORPORATION   (United States)

^b Sunnybrook Health Sciences Centre   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Animal models; Clinical trials; Cross correction; Lysosomal storage diseases; Parkinson's disease; Stem cells; Transplantation

Indexed keywords

BETA GLUCURONIDASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEURTURIN; PARVOVIRUS VECTOR; PEPTIDASE; RECOMBINANT ENZYME; TRIPEPTIDYL PEPTIDASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; CELL ENCAPSULATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DNA MODIFICATION; DRUG EFFICACY; DRUG MEGADOSE; ENGRAFTMENT; ENZYME REPLACEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYSOSOME STORAGE DISEASE; MICROENCAPSULATION; MULTIPOTENT STEM CELL; NERVE REGENERATION; NERVOUS SYSTEM; NEURAL STEM CELL; NEURONAL CEROID LIPOFUSCINOSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL GENE THERAPY; STEM CELL TRANSPLANTATION; VIRAL GENE THERAPY;

ANIMALS; HUMANS; LYSOSOMAL STORAGE DISEASES, NERVOUS SYSTEM; METABOLIC DISEASES; NEURODEGENERATIVE DISEASES; STEM CELL TRANSPLANTATION;

EID: 77649342578     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.12.015     Document Type: Review

References (119)

1. Androutsellis-Theotokis A., Rueger M.A., Park D.M., Mkhikian H., Korb E., Poser S.W., Walbridge S., Munasinghe J., Koretsky A.P., Lonser R.R., and McKay R.D. Targeting neural precursors in the adult brain rescues injured dopamine neurons. Proc Natl Acad Sci U.S.A. 106 (2009) 13570-13575
2. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163 (2000) 495-529
3. Bartus R.T., Dean III R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
4. Biffi A., De Palma M., Quattrini A., Del Carro U., Amadio S., Visigalli I., Sessa M., Fasano S., Brambilla R., Marchesini S., Bordignon C., and Naldini L. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest. 113 (2004) 1118-1129
5. Biran Y., Masters C.L., Barnham K.J., Bush A.I., and Adlard P.A. Pharmacotherapeutic targets in Alzheimer's disease. J. Cell Mol. Med. 13 (2009) 61-86
6. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., and Laferla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 13594-13599
7. Boelens J.J. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J. Inherit. Metab. Dis. 29 (2006) 413-420
8. Brasnjevic I., Steinbusch H.W., Schmitz C., and Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog. Neurobiol. 87 (2009) 212-251
9. Brundin P., Li J.Y., Holton J.L., Lindvall O., and Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 9 (2008) 741-745
10. Buchet D., Serguera C., Zennou V., Charneau P., and Mallet J. Long-term expression of beta-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system. Mol. Cell. Neurosci. 19 (2002) 389-401
11. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., Vidaud M., Abel U., Dal-Cortivo L., Caccavelli L., Mahlaoui N., Kiermer V., Mittelstaedt D., Bellesme C., Lahlou N., Lefrère F., Blanche S., Audit M., Payen E., Leboulch P., l'Homme B., Bougnères P., Von Kalle C., Fischer A., Cavazzana-Calvo M., and Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326 (2009) 818-823
12. Cicchetti F., Saporta S., Hauser R.A., Parent M., Saint-Pierre M., Sanberg P.R., Li X.J., Parker J.R., Chu Y., Mufson E.J., Kordower J.H., and Freeman T.B. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 12483-12488
13. Covaceuszach S., Capsoni S., Ugolini G., Spirito F., Vignone D., and Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr. Alzheimer. Res. 6 (2009) 158-170
14. Danielyan L., Schafer R., Ameln-Mayerhofer A., Buadze M., Geisler J., Klopfer T., Burkhardt U., Proksch B., Verleysdonk S., Ayturan M., Buniatian G.H., Gleiter C.H., and Frey W.H. Intranasal delivery of cells to the brain. Eur. J. Cell Biol. 88 (2009) 315-324
15. Dasilva K.A., Shaw J.E., and McLaurin J. Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp. Neurol. (2009)
16. Desnick R.J., and Schuchman E.H. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat. Rev. Genet. 3 (2002) 954-966
17. Emborg M.E., Moirano J., Raschke J., Bondarenko V., Zufferey R., Peng S., Ebert A.D., Joers V., Roitberg B., Holden J.E., Koprich J., Lipton J., Kordower J.H., and Aebischer P. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol. Dis. 36 (2009) 303-311
18. Enns G.M., and Huhn S.L. Central nervous system therapy for lysosomal storage disorders. Neurosurg. Focus 24 (2008) E12
19. Eriksdotter-Jonhagen, M., Linderoth, B., Aladellie, L., Lind, G., Nordberg, A., Almqvist, O., Bogdanovic, N., Andersson, C., Soderman, M., Wiberg, M., Kadir, A., Jelic, V., Wahlund, L.-O., Sellden, E., Winblad, B., Almqvist, P., Sundstrom, E., Seiger, A., Wahlberg, L., 2008. Encapsulated cell biodelivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients. In: Society for Neuroscience Abstracts. Poster 704.12.
20. Escolar M.L., Poe M.D., Provenzale J.M., Richards K.C., Allison J., Wood S., Wenger D.A., Pietryga D., Wall D., Champagne M., Morse R., Krivit W., and Kurtzberg J. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N. Engl. J. Med. 352 (2005) 2069-2081
21. Francis P.T., and Perry E.K. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord 22 Suppl. 17 (2007) S351-S357
22. Gaillard P.J., Visser C.C., and de Boer A.G. Targeted delivery across the blood-brain barrier. Expert. Opin. Drug. Deliv. 2 (2005) 299-309
23. Galpern W.R., and Lang A.E. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann. Neurol. 59 (2006) 449-458
24. Gratton J.P., Yu J., Griffith J.W., Babbitt R.W., Scotland R.S., Hickey R., Giordano F.J., and Sessa W.C. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat. Med. 9 (2003) 357-362
25. Greene P. Cell-based therapies in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 9 (2009) 292-297
26. Gupta A., Dawson V.L., and Dawson T.M. What causes cell death in Parkinson's disease?. Ann. Neurol. 64 Suppl. 2 (2008) S3-15
27. Hedlund E., and Perlmann T. Neuronal cell replacement in Parkinson's disease. J. Intern. Med. 266 (2009) 358-371
28. Hobert J.A., and Dawson G. Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future. Biochim. Biophys. Acta 1762 (2006) 945-953
29. Hodges B.L., and Cheng S.H. Cell and gene-based therapies for the lysosomal storage diseases. Curr. Gene Ther. 6 (2006) 227-241
30. Holtzman D.M. Alzheimer's disease: moving towards a vaccine. Nature 454 (2008) 418-420
31. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv. Drug Deliv. Rev. 60 (2008) 1209-1217
32. Jeyakumar M., Lee J.P., Sibson N.R., Lowe J.P., Stuckey D.J., Tester K., Fu G., Newlin R., Smith D.A., Snyder E.Y., and Platt F.M. Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. Stem Cells 27 (2009) 2362-2370
33. Jiang Y., Henderson D., Blackstad M., Chen A., Miller R.F., and Verfaillie C.M. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 100 Suppl. 1 (2003) 11854-11860
34. Jin H.K., Carter J.E., Huntley G.W., and Schuchman E.H. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J. Clin. Invest. 109 (2002) 1183-1191
35. Joannides A., Gaughwin P., Schwiening C., Majed H., Sterling J., Compston A., and Chandran S. Efficient generation of neural precursors from adult human skin: astrocytes promote neurogenesis from skin-derived stem cells. Lancet 364 (2004) 172-178
36. Kim S.U., and de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J. Neurosci. Res. 87 (2009) 2183-2200
37. Kogler G., Sensken S., Airey J.A., Trapp T., Muschen M., Feldhahn N., Liedtke S., Sorg R.V., Fischer J., Rosenbaum C., Greschat S., Knipper A., Bender J., Degistirici O., Gao J., Caplan A.I., Colletti E.J., Almeida-Porada G., Muller H.W., Zanjani E., and Wernet P. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med. 200 (2004) 123-135
38. Kordower J.H., and Brundin P. Propagation of host disease to grafted neurons: accumulating evidence. Exp. Neurol. 219 (2009) 368-371
39. Krabbe C., Zimmer J., and Meyer M. Neural transdifferentiation of mesenchymal stem cells-a critical review. APMIS 113 (2005) 831-844
40. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug. Deliv. Rev. 47 (2001) 65-81
41. Kringelbach M.L., Jenkinson N., Owen S.L., and Aziz T.Z. Translational principles of deep brain stimulation. Nat. Rev. Neurosci. 8 (2007) 623-635
42. Krivit W., Peters C., and Shapiro E.G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol. 12 (1999) 167-176
43. Krivit W., Shapiro E.G., Peters C., Wagner J.E., Cornu G., Kurtzberg J., Wenger D.A., Kolodny E.H., Vanier M.T., Loes D.J., Dusenbery K., and Lockman L.A. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N. Engl. J. Med. 338 (1998) 1119-1126
44. Krivit W., Sung J.H., Shapiro E.G., and Lockman L.A. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 4 (1995) 385-392
45. Lacorazza H.D., Flax J.D., Snyder E.Y., and Jendoubi M. Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat. Med. 2 (1996) 424-429
46. Lake B.D., Steward C.G., Oakhill A., Wilson J., and Perham T.G. Bone marrow transplantation in late infantile Batten disease and juvenile Batten disease. Neuropediatrics 28 (1997) 80-81
47. Lanari A., Amenta F., Silvestrelli G., Tomassoni D., and Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech. Ageing Dev. 127 (2006) 158-165
48. Lang A.E. When and how should treatment be started in Parkinson disease?. Neurology 72 (2009) S39-S43
49. Lee J.K., Jin H.K., and Bae J.S. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model. Neurosci. Lett. 450 (2009) 136-141
50. Lee J.P., Jeyakumar M., Gonzalez R., Takahashi H., Lee P.J., Baek R.C., Clark D., Rose H., Fu G., Clarke J., McKercher S., Meerloo J., Muller F.J., Park K.I., Butters T.D., Dwek R.A., Schwartz P., Tong G., Wenger D., Lipton S.A., Seyfried T.N., Platt F.M., and Snyder E.Y. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat. Med. 13 (2007) 439-447
51. Lensch M.W., Daheron L., and Schlaeger T.M. Pluripotent stem cells and their niches. Stem Cell Rev. 2 (2006) 185-201
52. Lim Z.Y., Ho A.Y., Abrahams S., Fensom A., Aldouri M., Pagliuca A., Shaw C., and Mufti G.J. Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transplant. 41 (2008) 831-832
53. Lindvall O. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp. Neurol. 209 (2008) 82-88
54. Lindvall O., and Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol. Sci. 30 (2009) 260-267
55. Luzi P., Rafi M.A., Zaka M., Rao H.Z., Curtis M., Vanier M.T., and Wenger D.A. Biochemical and pathological evaluation of long-lived mice with globoid cell leukodystrophy after bone marrow transplantation. Mol. Genet. Metab. 86 (2005) 150-159
56. Malm G., Gustafsson B., Berglund G., Lindstrom M., Naess K., Borgstrom B., von Dobeln U., and Ringden O. Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatr. 97 (2008) 1108-1112
57. Marks Jr. W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., and Bartus R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7 (2008) 400-408
58. Martinez-Serrano A., Rubio F.J., Navarro B., Bueno C., and Villa A. Human neural stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS. Curr. Gene Ther. 1 (2001) 279-299
59. McDonald J.W., and Howard M.J. Repairing the damaged spinal cord: a summary of our early success with embryonic stem cell transplantation and remyelination. Prog. Brain Res. 137 (2002) 299-309
60. McKinnis E.J., Sulzbacher S., Rutledge J.C., Sanders J., and Scott C.R. Bone marrow transplantation in Hunter syndrome. J. Pediatr. 129 (1996) 145-148
61. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., Chen F., Wong S.S., Mount H.T., Fraser P.E., Westaway D., and George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12 (2006) 801-808
62. Meikle P.J., Hopwood J.J., Clague A.E., and Carey W.F. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
63. Meng X.L., Shen J.S., Ohashi T., Maeda H., Kim S.U., and Eto Y. Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J. Neurosci. Res. 74 (2003) 266-277
64. Murua A., Portero A., Orive G., Hernandez R.M., de Castro M., and Pedraz J.L. Cell microencapsulation technology: towards clinical application. J. Control. Release 132 (2008) 76-83
65. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., and Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15 (2009) 331-337
66. Nakama H., Ohsugi K., Otsuki T., Date I., Kosuga M., Okuyama T., and Sakuragawa N. Encapsulation cell therapy for mucopolysaccharidosis type VII using genetically engineered immortalized human amniotic epithelial cells. Tohoku J. Exp. Med. 209 (2006) 23-32
67. Neufeld E.F. Enzyme replacement therapy. In: Platt F.M. (Ed). Lysosomal Disorders of the Brain (2004), Oxford University Press, Oxford 327-338
68. Nistor G.I., Totoiu M.O., Haque N., Carpenter M.K., and Keirstead H.S. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49 (2005) 385-396
69. O'Brien J.S., Miller A.L., Loverde A.W., and Veath M.L. Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts. Science 181 (1973) 753-755
70. Orive G., Anitua E., Pedraz J.L., and Emerich D.F. Biomaterials for promoting brain protection, repair and regeneration. Nat. Rev. Neurosci. 10 (2009) 682-692
71. Palmer T.D., Schwartz P.H., Taupin P., Kaspar B., Stein S.A., and Gage F.H. Cell culture. Progenitor cells from human brain after death. Nature 411 (2001) 42-43
72. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., Lerou P.H., Lensch M.W., and Daley G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451 (2008) 141-146
73. Peng S., Garzon D.J., Marchese M., Klein W., Ginsberg S.D., Francis B.M., Mount H.T., Mufson E.J., Salehi A., and Fahnestock M. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J. Neurosci. 29 (2009) 9321-9329
74. Peters C., Balthazor M., Shapiro E.G., King R.J., Kollman C., Hegland J.D., Henslee-Downey J., Trigg M.E., Cowan M.J., Sanders J., Bunin N., Weinstein H., Lenarsky C., Falk P., Harris R., Bowen T., Williams T.E., Grayson G.H., Warkentin P., Sender L., Cool V.A., Crittenden M., Packman S., Kaplan P., Lockman L.A., Anderson J., Krivit W., Dusenbery K., and Wagner J. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 87 (1996) 4894-4902
75. Platt F.M., and Lachmann R.H. Treating lysosomal storage disorders: current practice and future prospects. Biochim. Biophys. Acta 1793 (2009) 737-745
76. Porter M.T., Fluharty A.L., and Kihara H. Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts. Science 172 (1971) 1263-1265
77. Priller J., Flugel A., Wehner T., Boentert M., Haas C.A., Prinz M., Fernandez-Klett F., Prass K., Bechmann I., de Boer B.A., Frotscher M., Kreutzberg G.W., Persons D.A., and Dirnagl U. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7 (2001) 1356-1361
78. Ramaswamy S., Soderstrom K.E., and Kordower J.H. Trophic factors therapy in Parkinson's disease. Prog. Brain Res. 175 (2009) 201-216
79. Rosser A.E., Zietlow R., and Dunnett S.B. Stem cell transplantation for neurodegenerative diseases. Curr. Opin. Neurol. 20 (2007) 688-692
80. Safford K.M., Hicok K.C., Safford S.D., Halvorsen Y.D., Wilkison W.O., Gimble J.M., and Rice H.E. Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem. Biophys. Res. Commun. 294 (2002) 371-379
81. Schwartz P.H. Stem cell therapies for the lysosomal storage diseases - the quintessential neurodegenerative diseases. Curr. Stem Cell Res. Ther. 3 (2008) 88-98
82. Schwartz P.H., Bryant P.J., Fuja T.J., Su H., O'Dowd D.K., and Klassen H. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J. Neurosci. Res. 74 (2003) 838-851
83. Seow D., and Gauthier S. Pharmacotherapy of Alzheimer disease. Can. J. Psychiatry 52 (2007) 620-629
84. Shapiro E., Krivit W., Lockman L., Jambaqué I., Peters C., Cowan M., Harris R., Blanche S., Bordigoni P., Loes D., Ziegler R., Crittenden M., Ris D., Berg B., Cox C., Moser H., Fischer A., and Aubourg P. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 356 (2000) 713-718
85. Shapiro E.G., Lockman L.A., Balthazor M., and Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis. 18 (1995) 413-429
86. Shaw L.M., Korecka M., Clark C.M., Lee V.M., and Trojanowski J.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov. 6 (2007) 295-303
87. Shihabuddin L.S., Horner P.J., Ray J., and Gage F.H. Adult spinal cord stem cells generate neurons after transplantation in the adult dentate gyrus. J. Neurosci. 20 (2000) 8727-8735
88. Shihabuddin L.S., Numan S., Huff M.R., Dodge J.C., Clarke J., Macauley S.L., Yang W., Taksir T.V., Parsons G., Passini M.A., Gage F.H., and Stewart G.R. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-ick-A mouse leads to a marked decrease in lysosomal storage pathology. J. Neurosci. 24 (2004) 10642-10651
89. Simard A.R., and Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 18 (2004) 998-1000
90. Slevin J.T., Gash D.M., Smith C.D., Gerhardt G.A., Kryscio R., Chebrolu H., Walton A., Wagner R., and Young A.B. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg. 106 (2007) 614-620
91. Sly W.S., and Vogler C. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 5760-5762
92. Snyder E.Y., Taylor R.M., and Wolfe J.H. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 374 (1995) 367-370
93. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., Hargus G., Blak A., Cooper O., Mitalipova M., Isacson O., and Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136 (2009) 964-977
94. Sostak P., Theil D., Stepp H., Roeber S., Kretzschmar H.A., and Straube A. Detection of bone marrow-derived cells expressing a neural phenotype in the human brain. J. Neuropathol. Exp. Neurol 66 (2007) 110-116
95. Staba S.L., Escolar M.L., Poe M., Kim Y., Martin P.L., Szabolcs P., Allison-Thacker J., Wood S., Wenger D.A., Rubinstein P., Hopwood J.J., Krivit W., and Kurtzberg J. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N. Engl. J. Med. 350 (2004) 1960-1969
96. Stein J., Garty B.Z., Dror Y., Fenig E., Zeigler M., and Yaniv I. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur. J. Pediatr. 166 (2007) 663-666
97. Suzuki H., Taguchi T., Tanaka H., Kataoka H., Li Z., Muramatsu K., Gondo T., and Kawai S. Neurospheres induced from bone marrow stromal cells are multipotent for differentiation into neuron, astrocyte, and oligodendrocyte phenotypes. Biochem. Biophys. Res. Commun. 322 (2004) 918-922
98. Svendsen C.N., Caldwell M.A., and Ostenfeld T. Human neural stem cells: isolation, expansion and transplantation. Brain Pathol. 9 (1999) 499-513
99. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007) 861-872
100. Tamaki S., Eckert K., He D., Sutton R., Doshe M., Jain G., Tushinski R., Reitsma M., Harris B., Tsukamoto A., Gage F., Weissman I., and Uchida N. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J. Neurosci. Res. 69 (2002) 976-986
101. Taupin P. HuCNS-SC (StemCells). Curr. Opin. Mol. Ther. 8 (2006) 156-163
102. Taylor R.M., and Wolfe J.H. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat. Med. 3 (1997) 771-774
103. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., and Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998) 1145-1147
104. Toma J.G., McKenzie I.A., Bagli D., and Miller F.D. Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells 23 (2005) 727-737
105. Torrente Y., and Polli E. Mesenchymal stem cell transplantation for neurodegenerative diseases. Cell Transplant. 17 (2008) 1103-1113
106. Tsai M.S., Hwang S.M., Tsai Y.L., Cheng F.C., Lee J.L., and Chang Y.J. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol. Reprod. 74 (2006) 545-551
107. Tuszynski M.H., Thal L., Pay M., Salmon D.P., Hs U., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., Conner J., and Bakay R. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11 (2005) 551-555
108. van Praag H. Exercise and the brain: something to chew on. Trends Neurosci. 32 (2009) 283-290
109. Volkmann J., Albanese A., Kulisevsky J., Tornqvist A.L., Houeto J.L., Pidoux B., Bonnet A.M., Mendes A., Benabid A.L., Fraix V., Van Blercom N., Xie J., Obeso J., Rodriguez-Oroz M.C., Guridi J., Schnitzler A., Timmermann L., Gironell A.A., Molet J., Pascual-Sedano B., Rehncrona S., Moro E., Lang A.C., Lozano A.M., Bentivoglio A.R., Scerrati M., Contarino M.F., Romito L., Janssens M., and Agid Y. Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov. Disord. 24 (2009) 1154-1161
110. Vykhodtseva N., McDannold N., and Hynynen K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 48 (2008) 279-296
111. Walkley S.U., Thrall M.A., Dobrenis K., Huang M., March P.A., Siegel D.A., and Wurzelmann S. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 2970-2974
112. Weiss M.L., and Troyer D.L. Stem cells in the umbilical cord. Stem Cell Rev. 2 (2006) 155-162
113. Weksler M.E., Pawelec G., and Franceschi C. Immune therapy for age-related diseases. Trends Immunol. 30 (2009) 344-350
114. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., Broccoli V., Constantine-Paton M., Isacson O., and Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 5856-5861
115. Wisniewski T. AD vaccines: conclusions and future directions. CNS Neurol. Disord. Drug Targets 8 (2009) 160-166
116. Worgall S., Sondhi D., Hackett N.R., Kosofsky B., Kekatpure M.V., Neyzi N., Dyke J.P., Ballon D., Heier L., Greenwald B.M., Christos P., Mazumdar M., Souweidane M.M., Kaplitt M.G., and Crystal R.G. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19 (2008) 463-474
117. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., and Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007) 1917-1920
118. Zhang Y., Calon F., Zhu C., Boado R.J., and Pardridge W.M. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. 14 (2003) 1-12
119. Zuccato C., and Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5 (2009) 311-322